Albert Bourla, Pfizer CEO (Evan Vucci, AP Images)

Pfiz­er CEO points to IRA as a fac­tor that made Seagen an at­trac­tive tar­get

One of the rea­sons Pfiz­er sought to pur­chase Seagen, as part of a $43 bil­lion deal an­nounced this morn­ing, is that the Seat­tle-based biotech …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.